Vincerx Pharma, Inc. (VINC)
NASDAQ: VINC · IEX Real-Time Price · USD
0.889
+0.062 (7.52%)
At close: May 1, 2024, 4:00 PM
0.890
+0.001 (0.08%)
After-hours: May 1, 2024, 5:33 PM EDT
Company Description
Vincerx Pharma, Inc., a clinical-stage biopharmaceutical company, researches and develops therapies to address unmet medical needs for the treatment of cancer in the United States.
It is developing enitociclib, a cyclin-dependent kinase-9 inhibitor that is in Phase 1 clinical trials for treating patients with hematologic malignancies; and VIP236, a small molecule drug conjugate that is in Phase 1 clinical trials to treat solid tumors.
The company's preclinical stage product candidates include VIP943 and VIP924 for the treatment of hematologic malignancies.
Vincerx Pharma, Inc. was founded in 2019 is based in Palo Alto, California.
Vincerx Pharma, Inc.
| Country | United States |
| Founded | 2019 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 42 |
| CEO | Dr. Ahmed M. Hamdy M.D. |
Contact Details
Address: 260 Sheridan Avenue, Suite 400 Palo Alto, California 94306 United States | |
| Phone | 650-800-6676 |
| Website | vincerx.com |
Stock Details
| Ticker Symbol | VINC |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001796129 |
| CUSIP Number | 92731L106 |
| ISIN Number | US92731L1061 |
| Employer ID | 83-3197402 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Dr. Ahmed M. Hamdy M.D. | Co-Founder, Chairman and Chief Executive Officer |
| Dr. Raquel E. Izumi Ph.D. | Co-Founder, President, Chief Operating Officer, Secretary and Director |
| Alexander A. Seelenberger M.B.A. | Chief Financial Officer |
| Tom C. Thomas J.D. | Founder, General Counsel and Chief Legal Officer |
| Dr. John C. Byrd M.D. | Founder and Chairman of Scientific Advisory Board |
| Dr. Hans-Georg Lerchen Ph.D. | Chief Scientific Officer |
| Gabriela Jairala | Sr Executive Director of Investor Relations and Corporate Communications |
| Karen Quarford | Vice President of Quality Operations and Compliance |
| Melissa Merrick SPHR | Senior Director of People and Culture and Head of Human Resource |
| Dr. Beatrix Stelte-Ludwig Ph.D. | Executive Chief Development Officer |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Apr 29, 2024 | 424B5 | Filing |
| Apr 26, 2024 | 8-K | Current Report |
| Apr 25, 2024 | 8-K | Current Report |
| Apr 25, 2024 | 424B5 | Filing |
| Apr 10, 2024 | ARS | Filing |
| Apr 10, 2024 | DEFA14A | Additional definitive proxy soliciting materials and Rule 14(a)(12) material |
| Apr 10, 2024 | DEF 14A | Other definitive proxy statements |
| Apr 9, 2024 | SC 13G/A | [Amend] Statement of acquisition of beneficial ownership by individuals |
| Apr 8, 2024 | 8-K | Current Report |
| Mar 29, 2024 | 8-K | Current Report |